TAP1 and neoplasm: According to previous findings, low expression of ATM, TAP1 and LCN2 will increase the sensitivity of tumor cells to cisplatin (Matassa et al., 2016; Zhang et al., 2017; Huang et al., 2019), which is the same as our study conclusion and further illustrates the accuracy of our method.